Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Abstract

The aim of this study was to determine predictive factors for neutropenia after docetaxel-based systemic chemotherapy in patients with castration-resistant prostate cancer (CRPC). The study included 40 Korean CRPC patients who were treated with several cycles of docetaxel plus prednisolone from May 2005 to May 2012. Patients were evaluated for neutropenia risk factors and for the incidence of neutropenia. In this study, nine out of forty patients (22.5%) developed neutropenia during the first cycle of docetaxel-based systemic chemotherapy. Four experienced grade 2, three grade 3, and one grade 4 neutropenia. Multivariate analysis showed that pretreatment white blood cell (WBC) count (p=0.042), pretreatment neutrophil count (p=0.015), pretreatment serum creatinine level (p=0.027), and pretreatment serum albumin level (p=0.017) were significant predictive factors for neutropenia. In conclusion, pretreatment WBC counts, neutrophil counts, serum creatinine levels, and serum albumin levels proved to be significant independent risk factors for the development of neutropenia induced by docetaxel-based systemic chemotherapy in patients with CRPC.

Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype

“…Besides 6‐TGN levels, also excessively elevated 6‐MMPR levels have been associated with leucopenia . The increased risk for leucopenia with a lower baseline WBC count has also been reported in the setting of ganciclovir‐ and chemotherapy‐induced leucopenia . In contrast to a previous study, we did not find a correlation between concomitant 5‐ASA use and myelosuppression .…”

Delivering siRNA and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy

“…25 DTX usually cause hemotoxicity such as temporary drop in the number of white blood cells and neutropenia. 26 Thus, hematologic toxicity was evaluated in the study. There was no pronounced difference in the counts of red blood cells (RBC), white blood cells (WBC), hemoglobin (HGB), platelets (PLT), lymphocyte (LYM), and neutrophil granulocyte (GRN) tests after treatment (Figure 4E) among At-Lp/siRNA/DTX and other groups, indicating the dual peptides-modified combination delivery system was relatively safe at the test dose.…”

“…One of Mfsd2a-based strategies would destroy the BBB and enhance the uptake of drugs temporarily, thus potentially resulting some unexpected damage . DTX usually cause hemotoxicity such as temporary drop in the number of white blood cells and neutropenia . Thus, hematologic toxicity was evaluated in the study.…”

Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients

“…The rates of FN in these studies were 12.5% for patients with mHSPC who received docetaxel plus hormonal therapy, 7 and 14.0% for mCRPC patients treated with docetaxel‐based chemotherapy 8 . Similarly, a recent real‐world study in Korea reported an FN rate of 22.5% during the first cycle of docetaxel in mCRPC patients 9 …”